Texas Capital Bank Wealth Management Services Inc Has $9.25 Million Stake in Danaher Co. (NYSE:DHR)

Texas Capital Bank Wealth Management Services Inc grew its position in Danaher Co. (NYSE:DHR) by 3.5% in the third quarter, HoldingsChannel.com reports. The fund owned 33,260 shares of the conglomerate’s stock after buying an additional 1,122 shares during the period. Danaher comprises about 0.9% of Texas Capital Bank Wealth Management Services Inc’s portfolio, making the stock its 27th biggest holding. Texas Capital Bank Wealth Management Services Inc’s holdings in Danaher were worth $9,247,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. CarsonAllaria Wealth Management Ltd. bought a new stake in Danaher in the 2nd quarter valued at $25,000. nVerses Capital LLC acquired a new stake in shares of Danaher during the 2nd quarter worth about $25,000. Teachers Insurance & Annuity Association of America bought a new stake in shares of Danaher during the 3rd quarter worth about $39,000. MidAtlantic Capital Management Inc. acquired a new position in Danaher in the 3rd quarter valued at about $40,000. Finally, FSA Wealth Management LLC bought a new position in Danaher in the 3rd quarter valued at about $50,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

DHR has been the subject of several research reports. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a report on Thursday. Barclays lowered their target price on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 23rd. KeyCorp boosted their price target on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. Robert W. Baird lowered their price objective on Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Finally, Raymond James cut their target price on Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat, Danaher has an average rating of “Moderate Buy” and an average target price of $287.16.

Danaher Stock Down 3.5 %

Danaher stock opened at $227.88 on Friday. The company has a market capitalization of $164.59 billion, a PE ratio of 43.49, a PEG ratio of 4.43 and a beta of 0.83. Danaher Co. has a 12-month low of $215.68 and a 12-month high of $281.70. The firm’s fifty day moving average is $251.66 and its 200 day moving average is $258.69. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.14. The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.02 earnings per share. As a group, sell-side analysts predict that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were issued a $0.27 dividend. The ex-dividend date was Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.47%. Danaher’s dividend payout ratio is presently 20.61%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.